ELUTIA INC.

Elutia Inc. develops and commercializes proprietary biologic matrix and drug-eluting biomatrix products designed for surgical reconstruction, soft tissue repair, and cardiovascular applications. Operating through reporting segments including Women’s Health and Cardiovascular, the company provides products such as SimpliDerm, a human acellular dermal matrix for soft tissue repair, and cardiovascular matrices including ProxiCor, Tyke, and VasCure. Its customer base consists of healthcare facilities and hospitals, supplied via independent sales agents, alongside plastic, reconstructive, cardiovascular, and general surgeons who utilize these products to support tissue healing and reduce post-operative complications.

The company operates primarily within the United States, which generated all commercial product sales in 2025 following the cessation of international sales in May 2024. Elutia is headquartered in Gaithersburg, Maryland, where it leases approximately 26,598 square feet of production, laboratory, and administrative space to direct corporate activities and development. It also maintains a corporate office located in San Diego, California.

Summary of the business section of Elutia's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 26 employees, and 25 employees were employed full-time.”